Meet Andrew Wylie, CXO in Residence and drug discovery and development expert. As a CXO in Residence at Curie.Bio, Andy operates directly within the portfolio companies to help founders advance their drug discovery programs. Read more about the pharma experiences that led Andy to Curie.Bio, including his work on FDA-approved oncology drug SCEMBLIX, here. https://lnkd.in/eQEAQBw7
About us
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.
- Website
-
https://www.curie.bio
External link for Curie.Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Remote
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Remote, US
Employees at Curie.Bio
-
B. Christopher Kim
Executive at Bridge Biotherapeutics
-
John Herrmann
SVP, Portfolio Insights & Market Intelligence at Curie.Bio
-
Pallavur Sivakumar
Biotech Venture Capital | Curie.bio BIOTECHNOLOGY/ PHARMACEUTICAL LEADER| Biologics | Cell Therapy | Degraders/Small Molecules| Discovery and…
-
Christina Majer
Updates
-
What do you get when you combine a medicinal chemist obsessed with drug hunting, a LinkedIn celebrity and an Australian? You get Chris De Savi, one of Curie.Bio’s esteemed CSO Partners. Chris now shares his wealth of experience in bringing more than 10 drugs into the clinic with every Curie.Bio portfolio company that leverages a small molecule as part of their drug. More on Chris and the hard-earned expertise he brings to our portfolio companies: https://lnkd.in/egcrRT9E
-
Tired of commuting? Build blockbuster medicines with Curie.Bio, where you’ll get access to the world’s best people and R&D capabilities without having to leave your home office. Reach out to us: https://lnkd.in/e4NWnqwF
-
“I am a problem solver. It’s amazing how often a seemingly very complex problem has a surprisingly simple, elegant solution. The key to finding these solutions is asking the right questions.” After spending the last 8 years managing drug discovery projects at Novartis and contributing to multiple approved drugs, Jeroen Verheijen now lends his expertise to every set of founders we support. He shares details on the Curie.Bio website. https://lnkd.in/eDXBgMEX
-
“How can we make it happen?" That's the first question Katharina Kreymborg asks when she sees a new proposal from founders. From leading cancer immunotherapy research at Roche to building new companies at Versant Ventures, she has seen the drug development journey from many different angles. Now, she leverages these learnings to help founders at Curie.Bio create companies that are "scientifically exciting, financially profitable and operationally sound." Read more about Nina on our website. https://lnkd.in/gZpXB6QA
-
"Million Dollar Meetings" - This is what co-piloting with Curie.Bio truly looks like. Before we’ve even made an investment, Curie.Bio gives founders access to a world-class team of experts that would otherwise cost millions to recruit and retain. Pictured here is the team we dedicated to supporting one of our portfolio companies during the planning phase, pre-investment. This level of support ensures founders have the best possible chance to develop impactful medicines. After we've invested, our weekly meetings with portfolio companies typically involve 10-20 members from our team and private network, all focused on advancing workstreams to achieve critical, value-inflecting milestones.
-
"Drug discovery is akin to an extreme sport, where the exhilaration comes from being part of a team willing to take risks, tackle intricate challenges, and ultimately craft medicines that enhance human health." This insight comes from Wenyan Miao, who has recently joined our co-pilot team, bringing 25 years of experience in driving innovation in #autoimmune and #inflammatory disease therapies. Wenyan shares more about her passion for supporting Curie.Bio founders here. https://lnkd.in/gYzyf8NZ
-
Every founder we support hopes to invent a blockbuster medicine that saves the lives of thousands of patients. At Curie.Bio, we think the best way of helping founders accomplish that goal is by pairing them up with people who have already done it. Gregory Carven, Partner at Curie.Bio, led the discovery of Keytruda™ and was an early champion for #immunooncology at a time when most were unconvinced. He shares more about his passion for innovative science in service of patients on our website: https://lnkd.in/ehhZbAT3
-
Dennis Zaller has dedicated over 30 years to the discovery and development of new drugs that modify the immune system to help patients. In his own words, "The human immune system is incredibly powerful in the protection that it affords and the damage that it can inflict, so understanding how it works reveals a plethora of opportunities to find drugs." Check out highlights of Dennis' impressive career below, and read more here. https://lnkd.in/egmTWce2